Robert Jr. Baltera Acquires 30,000 Shares of Palisade Bio (NASDAQ:PALI) Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera acquired 30,000 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were bought at an average price of $2.03 per share, with a total value of $60,900.00. Following the completion of the purchase, the director owned 416,904 shares in the company, valued at $846,315.12. The trade was a 7.75% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Robert Jr. Baltera also recently made the following trade(s):

• On Monday, July 6th, Robert Jr. Baltera bought 20,000 shares of Palisade Bio stock. The stock was bought at an average price of $2.05 per share, for a total transaction of $41,000.00.
• On Thursday, July 2nd, Robert Jr. Baltera purchased 10,000 shares of Palisade Bio stock. The shares were purchased at an average cost of $1.98 per share, with a total value of $19,800.00.
• On Wednesday, July 1st, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The shares were purchased at an average cost of $1.98 per share, with a total value of $39,600.00.

Palisade Bio Stock Performance

Palisade Bio stock opened at $1.97 on Friday. Palisade Bio, Inc. has a one year low of $0.53 and a one year high of $2.86. The company has a 50-day simple moving average of $1.92 and a 200-day simple moving average of $1.92. The firm has a market capitalization of $341.95 million, a P/E ratio of -1.95 and a beta of 1.50.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). As a group, sell-side analysts forecast that Palisade Bio, Inc. will post -0.25 earnings per share for the current year.

Hedge Funds Weigh In On Palisade Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. CTC Alternative Strategies Ltd. bought a new stake in shares of Palisade Bio in the 1st quarter worth $31,000. Bank of America Corp DE boosted its stake in Palisade Bio by 181.1% during the first quarter. Bank of America Corp DE now owns 197,074 shares of the company’s stock valued at $345,000 after buying an additional 126,977 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Palisade Bio by 1.4% during the first quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock valued at $18,760,000 after buying an additional 149,118 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in Palisade Bio by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 2,264,845 shares of the company’s stock worth $3,963,000 after acquiring an additional 260,000 shares during the period. Finally, Orbimed Advisors LLC grew its holdings in Palisade Bio by 24.7% during the first quarter. Orbimed Advisors LLC now owns 2,333,000 shares of the company’s stock worth $4,083,000 after acquiring an additional 461,580 shares during the period. 11.79% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Oppenheimer set a $7.00 price target on Palisade Bio in a report on Tuesday, June 30th. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research report on Sunday, July 5th. Weiss Ratings upgraded Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 29th. HC Wainwright reiterated a “buy” rating and set a $2.00 price target on shares of Palisade Bio in a research report on Tuesday, June 30th. Finally, LADENBURG THALM/SH SH raised Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $8.83.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.